Developing a new type of radiation detector for precise cancer treatment
Ultrafast FLASH radiation therapy dosimetry
['FUNDING_R21'] · UNIVERSITY OF KANSAS MEDICAL CENTER · NIH-10840959
This study is working on a new type of radiation detector that can quickly and accurately measure radiation during FLASH therapy, a cutting-edge cancer treatment, to help make the therapy more effective for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KANSAS MEDICAL CENTER (nih funded) |
| Locations | 1 site (KANSAS CITY, UNITED STATES) |
| Trial ID | NIH-10840959 on ClinicalTrials.gov |
What this research studies
This research focuses on creating an innovative radiation detector that can measure radiation doses with exceptional speed and accuracy, specifically for FLASH radiation therapy, which is a promising cancer treatment. The project utilizes advanced low-gain-avalanche-detector technology combined with ultrafast electronics to achieve unprecedented temporal and spatial resolution in radiation measurement. By accurately capturing the details of radiation pulses, this technology aims to improve the effectiveness of radiation therapy for patients. The research is being conducted at the University of Kansas Medical Center and involves collaboration between engineers and biomedical researchers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing radiation therapy for cancer who may benefit from enhanced treatment precision.
Not a fit: Patients who are not receiving radiation therapy or those with conditions that do not require such treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer radiation therapy for cancer patients, potentially improving treatment outcomes.
How similar studies have performed: Other research has shown promise in developing advanced radiation detection technologies, but this specific approach using LGAD technology is novel and has not been extensively tested in clinical settings.
Where this research is happening
KANSAS CITY, UNITED STATES
- UNIVERSITY OF KANSAS MEDICAL CENTER — KANSAS CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, HAROLD HUI — UNIVERSITY OF KANSAS MEDICAL CENTER
- Study coordinator: LI, HAROLD HUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.